Whan In Pharmaceutical Co., Ltd.

As of June 30, 2026, Whan In Pharmaceutical Co., Ltd. carries a market capitalization of 179.66B, placing it among publicly traded companies globally. Its enterprise value stands at 113.59B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Whan In Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Whan In Pharmaceutical Co., Ltd. has 18.48M shares outstanding.

As of June 30, 2026, Whan In Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 8.41. The price-to-sales ratio is 0.63, and the price-to-book ratio stands at 0.42.

As of June 30, 2026, Whan In Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 3.53 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.09 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Whan In Pharmaceutical Co., Ltd. trades at an EV/FCF ratio of 7.64, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 113.59B versus a market cap of 179.66B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Whan In Pharmaceutical Co., Ltd. maintains a current ratio of 4.26, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.13, indicating conservative leverage, while an interest coverage ratio of 930.73 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Whan In Pharmaceutical Co., Ltd. posted a return on equity (ROE) of 5.08, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.44 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.48, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.07, useful for judging operating efficiency across full business cycles. The company generates approximately 410.31M in revenue per employee across its workforce of 666.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.86 indicates how many times Whan In Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Whan In Pharmaceutical Co., Ltd. recorded 5.10B in income tax expense. That works out to an effective tax rate of 19.97, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 25.56B, leaving 20.45B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Whan In Pharmaceutical Co., Ltd.'s stock has declined approximately 4.49% over the past 52 weeks. The 50-day moving average sits at 10,205.60, while the 200-day moving average is 10,403.65.

Over the twelve months ended June 30, 2026, Whan In Pharmaceutical Co., Ltd. generated 273.47B in revenue and converted that into 20.45B in net income, yielding earnings per share of 1,155.36. EBITDA reached 32.16B, while operating income came in at 22.31B.

As of June 30, 2026, Whan In Pharmaceutical Co., Ltd. holds 66.64B in cash and equivalents against 567.99M in total debt, resulting in a net debt position of -56.63B. Total book value stands at 425.47B, with working capital of 183.73B providing operational flexibility.

Whan In Pharmaceutical Co., Ltd. produced 17.67B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.83B in capital expenditures, free cash flow totaled 14.84B - equivalent to 838.28 per share.

Over the twelve months ended June 30, 2026, Whan In Pharmaceutical Co., Ltd. posted a gross margin of 36.23, reflecting its pricing power and cost economics. The operating margin of 8.16 and net profit margin of 7.48 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Whan In Pharmaceutical Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.62, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -2.89, meaning Whan In Pharmaceutical Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Whan In Pharmaceutical Co., Ltd.'s most recent stock split took place on April 26, 2010 with a 1:2 split ratio.

As of June 30, 2026, Whan In Pharmaceutical Co., Ltd. has an Altman Z-Score of 4.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.